THIS WEEK IN NEPHROLOGY: Dr. Parikh and I discuss exciting new developments Xenotransplantation for patients with renal insufficiency. February 26, 2025
Dr. McGuire, Dr. Jastreboff, and Dr. C. Michael Gibson discuss best practices for titration of GLP-1 medications for optimal weight loss. February 17, 2025 Disclosures: TBD
Dr. McGuire, Dr. Jastreboff, and Dr. C. Michael Gibson explore the question of what is the right weight reduction for each patient taking GLP-1 medications? February 12, 2025 Disclosures: TBD
Dr. McGuire, Dr. Jastreboff, and Dr. C. Michael Gibson discuss the SUMMIT trial and how GLP-1 agonists may be a new pillar in the treatment for HFpEF and obesity. January 30, 2025 Disclosures: TBD
Dr. McGuire, Dr. Jastreboff, and Dr. C. Michael Gibson discuss new oral semaglutide and the SOUL trial which lowered death, MI and stroke rates by 14% in patients with diabetes. December 18, 2024 Disclosures: TBD
Dr. McGuire, Dr. Jastreboff and Dr. C Michael Gibson discuss the SURMOUNT 1 Trial of Tirzepatide and how we may be able to diminish the progression from pre-diabetes to diabetes. December 9, 2024 Disclosures: TBD
Drs. Wazni and Gibson do a deep dive on the results of the OPTION Trial answering many of the questions that have come up. December 6, 2024
von Willebrand factor molecules cross link and form a net around a blood clot holding it together. Drs. Shahid Nimjee and Gibson discuss a new vWf inhibitor that breaks apart this net & opening closed arteries but leaving a patch of fibrin strands across the site of plaque rupture which would have been dissolved by fibrinolytics potentially causing bleeding. December 4, 2024 Disclosures: TBD
Dr. Stephen Nicholls and Dr. C. Michael Gibson Discuss: Safety and Efficacy of Obicetrapib in Patients With Heterozygous Familial Hypercholesterolemia (BROOKLYN) November 18, 2024 Disclosures: TBD
Dr. Katherine R Tuttle and Dr. C. Michael Gibson Discuss: Benefits of Semaglutide on Chronic Kidney Disease Outcomes by Cardiovascular Status or Risk in the FLOW trial November 18, 2024 Disclosures: TBD
